# CRISPR Therapeutics AG (CRSP) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $49.99, market value $4.8 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). CRISPR Therapeutics AG reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 192.0×**. Each dollar of revenue is priced at 192.0×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 2.5×**. The shares trade at 2.5× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -7.8%** (5-yr avg -5.3%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -30.3%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -26.7%**. Return on all capital, debt included, is -26.7%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -20.1%**. Each dollar of assets produces -20.1% of profit.

## Growth
- **Revenue growth (1 yr): -90.6%** (3-yr 43.1%/yr, 5-yr 37.3%/yr). Revenue fell 90.6% over the last year, against 37.3% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): -49.1%**. Earnings per share fell 49.1%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 0.00**. Debt is 0.00 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 0.7×**. It would take 0.7 years of operating earnings to repay net borrowings, within the comfortable range.
- **Current ratio: 13.32** (quick 13.32). Current assets cover the next year's liabilities 13.32 times.
- **Altman Z-score: 9.64**. A Z-score of 9.64 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. CRISPR Therapeutics AG does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (19 analysts). 19 analysts cover CRISPR Therapeutics AG; the consensus is buy, with an average price target of $85.63 (+71% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -21.9%** (YTD -4.7%, 3-mo 0.8%). The shares are down 21.9% over twelve months including dividends.
- **From 52-week high: -21.2%** (13.3% above the low). Trading 21% below its 52-week high.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 44**. An RSI of 44 is neutral.
- **Beta (1 yr): 1.87** (volatility 58%). Beta of 1.87 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=CRSP · Page: https://foliofundamentals.com/stocks/crsp

Not investment advice.